These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7660948)

  • 1. Chemotherapeutic options in HIV infection.
    Cox S; Palmer S; Aperia K; Wahren B
    Adv Exp Med Biol; 1994; 370():443-51. PubMed ID: 7660948
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
    Erice A; Balfour HH
    Clin Infect Dis; 1994 Feb; 18(2):149-56. PubMed ID: 7512829
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
    J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular metabolism of zidovudine and stavudine in combination.
    Hoggard P; Khoo S; Barry M; Back D
    J Infect Dis; 1996 Sep; 174(3):671-2. PubMed ID: 8769637
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
    J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine).
    Bergamini A; Ventura L; Mancino G; Capozzi M; Placido R; Salanitro A; Cappannoli L; Faggioli E; Stoler A; Rocchi G
    J Infect Dis; 1996 Jul; 174(1):214-8. PubMed ID: 8655998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 9. [Reverse transcriptase inhibitors as anti-HIV agents].
    Shirasaka T; Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():192-9. PubMed ID: 7505846
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
    Winslow DL; Mayers D; Scarnati H; Lane J; Bincsik A; Otto MJ
    AIDS; 1994 Jun; 8(6):753-6. PubMed ID: 8086132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance.
    Karlsson A; Parsmyr K; Aperia K; Sandström E; Fenyö EM; Albert J
    J Infect Dis; 1994 Dec; 170(6):1367-75. PubMed ID: 7995974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
    Bridges CG; Taylor DL; Ahmed PS; Brennan TM; Hornsperger JM; Navé JF; Casara P; Tyms AS
    Antimicrob Agents Chemother; 1996 May; 40(5):1072-7. PubMed ID: 8723443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to anti-human immunodeficiency virus therapeutic agents.
    Emini EA
    Adv Exp Med Biol; 1995; 390():187-95. PubMed ID: 8718613
    [No Abstract]   [Full Text] [Related]  

  • 15. Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen.
    Ennen J; Werner K; Kühne FW; Kurth R
    AIDS; 1993 Sep; 7(9):1205-12. PubMed ID: 8216977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine triple combo results released.
    Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
    Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
    Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
    Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma viral load, CD4+ cell counts, and HIV-1 production by cells.
    Levy JA; Ramachandran B; Barker E; Guthrie J; Elbeik T
    Science; 1996 Feb; 271(5249):670-1. PubMed ID: 8571134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.